VINCRISTINE FOR REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA IN PREGNANCY - A CASE-REPORT

BACKGROUND: Autoimmune thrombocytopenic purpura is it common disease d uring pregnancy. Newborns of affected mothers commonly develop thrombo cytopenia. Standard therapy consists of corticosteroids, hyperimmune g amma globulin and splenectomy. CASE: Severe autoimmune thrombocytopeni c purpura was diagnosed in a 22-year-old woman, gravida 2, para 1, at 28 weeks' gestation. A sufficient response was obtained after vincrist ine was added to the treatment with corticosteroids, hyperimmune gamma globulin and danazole. A male infant weighing 2,545 g was delivered b y cesarean section at 33.5 weeks' gestation. There were no maternal or fetal complications except for severe newborn thrombocytopenia, which resolved with medical therapy. CONCLUSION: Vincristine has been used in all trimesters of pregnancy, Vincristine outcomes in most cases. Th is is the first reported case of successful vincristine treatment for autoimmune thrombocytopenic purpura in pregnancy. Vincristine, when ca refully used, offers an option for unusually refractory cases of autoi mmune thrombocytopenic purpura before delivery.